Annual Conference of Indian Society for Neuro-Oncology 2016

<ul><li>Largest annual congregation of neuro-oncology specialists- neurosurgeons, radiation oncologists, medical oncologists, neurologists, basic scientists.</li><li>Ab Guha Oration by past SNO president and Director of Neuro-oncology programme at Harvard.</li><li>Key note sessions on the theme of the conference namely- Emerging WHO classification of brain tumors &amp; Benign brain tumors- Surgical and radio- surgical management.</li><li>&ldquo;Do not miss&rdquo; sessions on the latest path breaking research in neuro-oncology.</li><li>Best Indian research being presented as poster and oral presentations.</li><li>Best International and national experts to debate on key issues in neurooncology</li></ul>

<p><strong>Abstracts must be submitted on-line via the isnocon2016.in website.</strong></p><p><strong>Abstracts sent by mail, fax or e-mail will NOT be accepted.</strong></p><p><strong>Deadline abstract submission: 1st March, 2016.</strong></p><p><strong>The optimal Browser for submission is MS INTERNET EXPLORER.</strong></p><h6>Abstract Regulations</h6><p>With the submission of an abstract to ISNOCON 2016, the presenting author:</p><ul><li>confirms that all authors are aware of and agree to the content of the abstract and support the data presented;</li><li>accepts to be the contact person for all correspondence about the abstract and inform co-authors about its status;</li><li>warrants that the data and conclusions presented in the abstract have not been published prior to the date of the ISNOCON. Abstracts containing previously published material will be rejected;</li><li>states that for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority, and properly informed consent give where appropriate;</li><li>accepts responsibility for the accuracy of the submitted abstract;</li><li>acknowledges that once the abstract is submitted, changes, corrections or rewording are possible until deadline of abstract submission <strong>(1st March, 2016);</strong></li></ul><p>Careful typing and proof-reading are essential as the abstract will appear, if accepted, as submitted.</p><h6>Affirmation regarding Registration</h6><p><strong>Important Note</strong>: At least 1 author (presenting author) of this abstract is obliged to register and pay the congress registration fee <strong>within 3 weeks</strong> after notification on acceptance. In the event of non-fulfillment the abstract will be <strong>withdrawn</strong> by the organisers.</p><h6>Acceptance and Selection of Abstracts</h6><p>All submitted abstracts will be reviewed by the Scientific Programme Committee in <strong>March 2016</strong>, and authors will be notified by email at the latest in mid March 2016. Abstract selection: Some accepted abstracts will be selected for oral presentation, some will be presented as posters.</p><h6>Abstract Format</h6><ul><li>The abstract must be submitted in good English.</li><li>The text must not exceed 2500 characters excluding spaces, title and authors.</li><li>A maximum of two institutions per author is allowed.</li><li>No more than 10 authors can be listed.</li><li>No tables, no graphs or illustrations are allowed.</li><li>No literature must be cited.</li></ul><h6>Submission topics</h6><p>Please select only ONE topic that refers to the main subject of your abstract</p><ol><li>Cell biology and signaling</li><li>Epidemiology</li><li>Quality of life</li><li>Immunology and immunotherapy</li><li>In vitro / in vivo models</li><li>BIOMARKERS</li><li>Neuroimaging of brain tumours</li><li>Glioblastom and Anaplastic gliomas</li><li>Low grade gliomas</li><li>Pediatric brain tumours</li><li>Meningiomas</li><li>Spinal cord tumours</li><li>Brain and leptomeningeal metastases</li><li>Neurotoxicity and neuroprotection</li><li>Paraneoplastic neurological syndromes</li><li>Supportive and palliative care</li><li>Primary central nervous system lymphoma (PCNSL)</li><li>New developments in surgery</li><li>New developments in radiotherapy</li><li>New developments in drug delivery</li><li>Miscellaneous</li></ol>